8-K: BriaCell Therapeutics Announces Positive Clinical and Regulatory Updates

BriaCell Therapeutics Corp. announced a poster presentation at the SITC annual meeting, positive feedback from the FDA for its prostate cancer therapy, and encouraging overall survival data for its breast cancer treatment.

Summary

• BriaCell Therapeutics Corp. announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting to be held November 6-10, 2024.
• The company received positive feedback from the FDA regarding its Pre-Investigational New Drug (Pre-IND) meeting for Bria-PROS+ in prostate cancer, which waives the need for animal toxicology and pharmacokinetic studies.
• BriaCell also reported a median overall survival of 15.6 months in a Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor for late-stage metastatic breast cancer, compared to 6.7-9.3 months reported in the literature for similar patients.
• The Phase 2 study included 54 heavily pre-treated metastatic breast cancer patients with an average of 6 prior treatments.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the encouraging clinical data and regulatory progress. The improved survival rates and FDA feedback are strong indicators of potential success.

Positives

• The FDA's positive feedback for Bria-PROS+ significantly simplifies the development pathway by waiving animal studies.
• The 15.6-month median overall survival in the Phase 2 study represents a substantial improvement compared to historical data.
• The company is advancing multiple immunotherapy candidates for different cancer types.
• There have been no drug-related discontinuations in the Bria-IMT study to date.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the success of clinical trials and regulatory approvals.
• The company's future results are based on assumptions that may not prove to be accurate.
• The company is reliant on the success of its clinical trials and regulatory approvals.

Future Outlook

BriaCell plans to continue clinical investigations of its immunotherapy candidates, with the goal of establishing Bria-IMT as a new standard of care for metastatic breast cancer and advancing Bria-PROS+ for prostate cancer.

Management Comments

• Miguel Lopez-Lago, PhD, BriaCell's Chief Scientific Officer, stated, 'We are thrilled to be invited to present our data at this prestigious conference.'
• Dr. William V. Williams, BriaCell's President and CEO, stated, 'We were truly impressed by the FDA team of experts keen interest in Bria-PROS+ as a potential novel personalized approach for advanced prostate cancer.'
• Dr. William V. Williams, BriaCell's President and CEO, stated, 'The nearly two-fold overall survival benefit we are seeing with the Bria-IMT regimen, together with the similar previously reported approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients.'
• Sara A. Hurvitz, MD, Professor of Medicine, Fred Hutch Cancer Center and University of Washington and BriaCell medical advisory board member, stated, 'The BriaCell early data is quite encouraging from both efficacy and tolerability standpoints.'
• Giuseppe Del Priore, MD, MPH, BriaCell's Chief Medical Officer, stated, 'The Bria-IMT regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments including immune check point inhibitors and antibody drug conjugates.'

Industry Context

The announcements highlight BriaCell's progress in the competitive field of cancer immunotherapy, where novel approaches and improved survival rates are highly sought after. The positive FDA feedback and survival data position BriaCell as a potential player in the treatment of breast and prostate cancer.

Comparison to Industry Standards

• The reported median overall survival of 15.6 months for Bria-IMT in metastatic breast cancer patients is significantly higher than the 6.7-9.3 months reported in studies of similar patient populations, such as those by Bardia et al., Tripathy et al., OShaughnessy et al., and Cortes et al.
• The FDA waiving animal toxicology and pharmacokinetic studies for Bria-PROS+ is a positive development, as it reduces the time and cost associated with bringing a new drug to market, which is a common hurdle for many biotech companies.
• The company's approach of combining Bria-IMT with immune checkpoint inhibitors aligns with current trends in cancer immunotherapy, which often involve combination therapies to enhance efficacy.

Stakeholder Impact

• Shareholders may view the positive clinical and regulatory updates favorably, potentially increasing the company's stock value.
• Patients with metastatic breast and prostate cancer may benefit from the development of new treatment options.
• Employees may be motivated by the company's progress and potential to impact cancer care.

Next Steps

• BriaCell will present a poster at the SITC Annual Meeting.
• The company plans to file an IND and conduct a Phase 1/2 study of Bria-PROS+ in prostate cancer.
• BriaCell will continue its Phase 3 pivotal study of Bria-IMT in metastatic breast cancer.

Key Dates

Keywords

immunotherapy, cancer, breast cancer, prostate cancer, clinical trial, FDA, Bria-IMT, Bria-PROS+, overall survival, SITC